Basic Sotacor Information

• INN (International Nonproprietary Name): Sotalol hydrochloride
• Brand Names Available In Canada (English): Betapace; Betapace AF; Sorine; generic sotalol from manufacturers such as Mylan, Teva, Apotex
• ATC Code: C07AA07 (C07 = Beta blocking agents; AA = Non-selective beta blocking agents; 07 = Sotalol)
• Forms & Dosages: Tablets in strengths 80 mg, 120 mg, 160 mg, 240 mg; oral liquid generally unlicensed/compounded for paediatric use
• Manufacturers In Canada (English): Mylan, Teva, Apotex and other local generics
• Registration Status In Canada (English): Prescription product marketed in Canada under brand and generic names; confirm Drug Identification Number (DIN) in the Health Canada Drug Product Database before dispensing
• OTC / Rx Classification: Prescription only (Rx) in Canada and other major regions

Critical Warnings And Restrictions In Canada

Sotalol is a high-risk antiarrhythmic that requires careful handling in Canada and elsewhere.

Initiation frequently occurs in hospital with continuous ECG and renal function monitoring because dose-related QT prolongation and torsades de pointes are real dangers.

Many product monographs and clinical protocols recommend inpatient initiation and at least 72 hours of telemetry while titrating dose.

• Absolute Contraindications: bradycardia; high‑grade atrioventricular block unless a pacemaker is present; congenital or acquired long QT syndrome; overt heart failure; creatinine clearance under 40 mL/min with standard regimens; known hypersensitivity to sotalol.
• Relative Contraindications: asthma or COPD because sotalol is non‑selective beta blockade; significant electrolyte disturbances (hypokalemia, hypomagnesemia); renal dysfunction that requires dose interval adjustment.

Use a checklist before any inpatient initiation: obtain a baseline 12‑lead ECG, check serum potassium and magnesium, measure creatinine and calculate CrCl, perform medication reconciliation, and plan for at least 72 hours of continuous telemetry.

Health Canada and MedEffect accept adverse‑event reports and clinicians should be encouraged to report suspected reactions.

High-Risk Groups

Elderly patients require lower starting doses and closer renal monitoring because age raises the chance of reduced creatinine clearance and bradycardia.

Pregnant persons should use sotalol only if clearly needed and after discussion of risks and benefits with the prescriber and obstetrics team.

Indigenous peoples with a higher prevalence of chronic kidney disease or limited access to telemetry need culturally safe care pathways and documented informed consent when sotalol is considered.

Lower starting doses, renal dosing adjustments, and clear access to ECG/telemetry must be arranged for these groups.

Interaction With Activities

Sotalol can cause dizziness, syncope and significant bradycardia that affect driving and operation of heavy machinery.

Patients should not drive until they know how sotalol affects them.

For safety‑sensitive work, physician clearance may be required under provincial occupational fitness rules.

Q&A — Can I Drive After Taking It In Canada?

Not until you know how it affects you.

If you experience dizziness, syncope, marked slowing of the heart rate, or new visual disturbance, do not drive and seek medical assessment.

Follow provincial licensing rules and inform your employer if your duties are safety‑sensitive.

Usage Basics For Canadians

INN And Brand Names Available In Canada

Sotalol hydrochloride is the INN used in Canada and internationally.

It is commonly marketed as Betapace and Betapace AF and sold as generics labelled sotalol or generic sotalol by manufacturers such as Mylan, Teva and Apotex.

• Betapace — tablets typically available in multiple strengths.
• Betapace AF — formulation and labelling for atrial fibrillation/flutter indication.
• Sorine and generic sotalol — manufacturer and packaging depend on supplier.
• Common strengths seen in practice: 80 mg, 120 mg, 160 mg, 240 mg tablets.

Legal Classification Under Health Canada

• Prescription Validity: Sotalol is prescription‑only; prescriptions must meet provincial rules and pharmacists should verify indication and monitoring before supply.
• Substitution Rules: Betapace AF carries specific atrial‑fibrillation labelling and is not interchangeable with Betapace for ventricular arrhythmia without clinical advice.
• Bilingual Labelling: Packaging and patient information must comply with federal and Quebec bilingual requirements where applicable.
• Pharmacist Counselling Obligations: Pharmacies must perform medication reconciliation, confirm recent ECG and renal function, and counsel on side effects and monitoring.

Canadian Dosing Guide

Standard Regimens

Typical adult starting dose for ventricular arrhythmias is 80 mg twice daily.

For atrial fibrillation/flutter, Betapace AF is usually started at 80 mg twice daily and can be titrated to 160 mg twice daily under supervision.

Titration must be based on ECG and renal function and inpatient initiation is often mandatory.

Adjustments For Comorbidities

Reduce starting doses or extend dosing intervals when creatinine clearance is reduced.

Avoid standard regimens if CrCl is below 40 mL/min without specialist advice.

In elderly patients initiate at lower doses and monitor for bradycardia and masking of hypoglycaemia in diabetics.

• Checklist For Baseline Tests: 12‑lead ECG, serum K+, Mg2+, creatinine and calculated CrCl.

Q&A — What If I Miss A Dose Under My Provincial Drug Plan?

Take the missed dose as soon as you remember unless it is close to the next scheduled dose.

Do not double up doses to make up for a missed one.

If treatment was interrupted for more than 48–72 hours contact your prescriber or pharmacist before restarting and obtain ECG/monitoring as advised.

Interaction Chart (Canadian Context)

Food And Drinks

Alcohol can worsen bradycardia, hypotension and dizziness when starting or titrating sotalol.

Heavy caffeine intake may provoke palpitations and confound symptom assessment during titration.

• Practical Counselling Points: limit alcohol until dose is stable; stay well hydrated; avoid large caffeine spikes around dosing.

Common Drug Conflicts

• Checklist: perform medication reconciliation at every refill and consult provincial drug interaction tools and formulary alerts used by Canadian pharmacists.

User Reports And Trends In Canada

Canadian Patient Forums And Review Platforms

Patients commonly report fatigue, dizziness and symptomatic bradycardia after starting sotalol.

Many patients express concern about the need for ECG monitoring and inpatient stays during titration.

Clinicians should validate subjective reports with objective monitoring and report suspected adverse events to Health Canada (MedEffect).

Community Pharmacy Feedback

Community pharmacists at major chains routinely flag access barriers such as the need for inpatient initiation, prior authorizations and exceptional‑access forms for provincial programs.

Timely laboratory and ECG results are often required before dispensing an initial supply.

• Typical Patient Experiences: difficulty arranging hospitalization for initiation, anxiety about torsades risk, confusion around brand interchangeability between Betapace and Betapace AF.
• Pharmacist Checklist: confirm DIN, check recent creatinine and ECG, counsel on driving and work restrictions.

E‑E‑A‑T Note: clinicians should reference peer‑reviewed studies and provincial formulary notes when using patient‑reported patterns to inform care.

Access And Purchase Options

National Pharmacy Chains And In-Store Access

Major chains in Canada such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu stock generics when available, but a prescription is always required for legal dispensing.

Pharmacies can often coordinate with prescribers for urgent fills or special authorizations to provincial drug plans.

Most community pharmacies will request recent renal function and ECG documentation before supplying sotalol for initiation or titration.

Online Pharmacies And Provincial Restrictions

Many Canadian online pharmacies can dispense on a valid prescription and are licensed provincially to ship within Canada.

Remote prescribing may be possible in some provinces, but inpatient initiation requirements usually limit telemedicine starts for new sotalol therapy.

• Patient Checklist Before Ordering: bring recent labs and ECG, confirm coverage, check DIN, and arrange a monitoring plan with prescriber and pharmacy.

Note: paediatric oral liquid formulations are generally unlicensed and require compounding; discuss options with your pharmacist.

In our online pharmacy, sotacor is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Mechanism And Pharmacology

Simplified Explanation

Sotalol is a non‑selective beta‑blocker that also has Class III antiarrhythmic effects.

It slows heart rate through beta blockade and prolongs the cardiac action potential via potassium channel effects, which helps control atrial and ventricular arrhythmias.

Those same effects increase the risk of QT prolongation and torsades de pointes, especially during initiation and dose escalation.

Clinical Terms

• QT Interval Prolongation: prolongation of the heart’s electrical repolarization on ECG that raises risk of torsades de pointes.
• Torsades De Pointes: a potentially life‑threatening polymorphic ventricular tachycardia associated with prolonged QT.
• Bradycardia: slow heart rate that can cause dizziness, syncope or worsen heart failure.
• Creatinine Clearance (CrCl): an estimate of kidney function used to adjust sotalol dosing.

• Key Pharmacokinetic Points: renal elimination predominates; sotalol undergoes minimal hepatic metabolism; dose adjustment based on CrCl is required.
• Safety Emphasis: proarrhythmia risk is greatest during initial inpatient titration and with renal impairment.

Recommended Visual For Handouts: a simple flow diagram showing mechanism → intended effect → primary risks can help patients understand why monitoring matters.

Indications And Off‑Label Uses In Canada

Approved Indications

Sotalol is indicated for the treatment of life‑threatening ventricular arrhythmias and for maintenance of sinus rhythm in atrial fibrillation and flutter when using Betapace AF labelling.

Clinicians and pharmacists must check product monographs and the Health Canada Drug Product Database for current DINs and labelled uses before prescribing or dispensing.

Common Off‑Label Practices

Cardiologists may use sotalol off‑label for some recurrent supraventricular tachycardias under close supervision.

Any off‑label use requires informed consent and a documented monitoring plan including ECG and renal follow‑up.

• Informed Consent Checklist: discuss risks of QT prolongation/torsades, need for inpatient telemetry, alternatives and monitoring schedule.

Key Clinical Findings

Canadian And International Studies 2022–2025

Recent literature continues to show sotalol provides effective rhythm control for selected atrial and ventricular arrhythmias but carries a quantifiable early‑titration proarrhythmia risk.

Canadian cohort data highlight the importance of renal dosing and inpatient initiation to reduce torsades risk.

Clinicians should consult peer‑reviewed trials and Health Canada safety communications when making treatment decisions.

Ongoing Health Canada Safety Monitoring

Healthcare providers and pharmacists should routinely check MedEffect and provincial drug safety bulletins for label changes, DIN updates or recalls.

• Outcomes To Monitor: efficacy in rhythm control, incidence of torsades, rates of symptomatic bradycardia, and hospital readmissions during titration.

Alternatives Matrix

Comparable Medicines With DIN In Canada

Alternatives to sotalol include amiodarone, dronedarone (Multaq), flecainide, propafenone and mexiletine depending on the arrhythmia and patient comorbidities.

Pros And Cons Checklist

• When Sotalol Is Preferred: patients needing both beta‑block and Class III effects where monitoring resources are available.
• When Alternatives Are Favoured: presence of significant renal impairment, severe heart failure, or contraindications to beta blockade.

Common Questions From Canadian Patients

• What Are The Most Common Side Effects? Bradycardia, fatigue, dizziness, headache, gastrointestinal upset, and the risk of QT prolongation.
• Can I Stop It Suddenly? No; abrupt cessation can precipitate arrhythmia or angina in some patients — consult your prescriber before stopping.
• Pregnancy And Breastfeeding? Use only if clearly needed; discuss with obstetrics and the prescriber because safety data are limited.
• Who To Call And When To Seek Emergency Care? Seek urgent care for syncope, palpitations with fainting, chest pain or severe shortness of breath.

• Before Your First Dose Checklist: confirm baseline ECG, recent creatinine, complete medication list, arrange monitoring and driving/work counselling.

For definitive policy and formulary coverage consult the Health Canada monograph and provincial formularies.

Coverage And Purchase Comparison

Coverage Table

Step‑By‑Step Purchase Checklist For Canadian Patients

1. Obtain a prescription and bring a recent ECG and creatinine result.
2. Confirm DIN and discuss brand/generic interchangeability with your prescriber and pharmacist.
3. Check your provincial plan for prior authorization or exceptional‑access criteria.
4. Present prescription and ID to the pharmacy when collecting medication.
5. Arrange a monitoring plan including telemetry if initiating treatment and follow‑up ECGs for titration.

Contact your provincial drug benefit office or pharmacist for exact copayments and prior‑authorization steps.

Registration And Regulation

Health Canada Approval

Sotalol products in Canada are prescription drugs and their approval information and labelled monographs are maintained in the Health Canada Drug Product Database.

Each marketed product has a Drug Identification Number (DIN) that should be checked when prescribing or dispensing.

DIN Number And Labelling Requirements

• DIN: Varies by manufacturer and strength; confirm the exact DIN in the Health Canada database.
• Bilingual Labelling: Packaging must meet federal bilingual requirements and additional Quebec rules when applicable.
• Pharmacovigilance: Adverse events should be reported to Health Canada (MedEffect) and local public health as required.

• Pharmacy Procedural Checklist: verify DIN, check for recalls before dispensing, ensure patient information is provided in the required language(s).

Storage And Handling

Standard Canadian Household Conditions

Store sotalol tablets at room temperature, typically 20–25°C, protected from heat and moisture.

Do not refrigerate tablets.

Take care when transporting in extreme Canadian seasonal temperatures; keep tablets in the original container.

Cold‑Chain Requirements

No cold chain is required for commercial sotalol tablets.

For compounded oral liquids used in paediatrics, follow pharmacist instructions for beyond‑use dating and storage.

• Traveller Checklist: carry medication in the original labelled container, bring a copy of the prescription and prescriber letter, keep medication in carry‑on luggage, and avoid extreme heat or cold.
• Proper Disposal: return unused tablets to a community pharmacy take‑back or use municipal medication disposal programs.

Guidelines For Proper Use

Canadian Pharmacist Guidance

Before dispensing confirm the indication, review the ECG and renal function, reconcile interacting medications, and counsel on adverse effects and driving/work restrictions.

Document counselling and monitoring plans in the pharmacy record.

Provincial Health Authority Recommendations

Follow local hospital initiation protocols that typically recommend at least 72 hours of telemetry during initial titration.

Adhere to provincial formulary prior‑authorization steps, and seek cardiology input for dose escalation or when CrCl is under 40 mL/min.

• Follow‑Up Checklist: ECG at each dose change, periodic creatinine and electrolytes, and a symptom log for palpitations or syncope.
• Emergency Actions: stop medication only under medical advice and seek urgent care for fainting, sustained palpitations or chest pain.
• Report adverse events to Health Canada MedEffect and the local health authority.

Delivery Across Canada (English)